[go: up one dir, main page]

MX2007007568A - Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina. - Google Patents

Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina.

Info

Publication number
MX2007007568A
MX2007007568A MX2007007568A MX2007007568A MX2007007568A MX 2007007568 A MX2007007568 A MX 2007007568A MX 2007007568 A MX2007007568 A MX 2007007568A MX 2007007568 A MX2007007568 A MX 2007007568A MX 2007007568 A MX2007007568 A MX 2007007568A
Authority
MX
Mexico
Prior art keywords
vkorci
genetic variants
polymorphism
warfarin sensitivity
warfarin
Prior art date
Application number
MX2007007568A
Other languages
English (en)
Inventor
Hsiang-Yu Yuan
Jin-Jer Chen
Yaun-Tsong Cheng
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007007568(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of MX2007007568A publication Critical patent/MX2007007568A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Descubrimos que un polimorfismo en el promotor del gen VKORCI esta asociado con la sensibilidad a la warfarina. Este polimorfismo puede explicar tanto las diferencias entre individuos como las diferencias entre razas en los requerimientos de dosis de warfarina. Adicionalmente, el polimorfismo tambien esta asociado con la actividad del promotor. Asi, la secuencia o actividad del promotor del gen VKORCI de un sujeto se puede utilizar para predecir cuanta warfarina se debe prescribir para el sujeto. Se proporcionan metodos y composiciones relevantes.
MX2007007568A 2004-12-21 2005-12-21 Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina. MX2007007568A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63883704P 2004-12-21 2004-12-21
US67969405P 2005-05-10 2005-05-10
PCT/US2005/046869 WO2006069339A2 (en) 2004-12-21 2005-12-21 Genetic variants of vkorci predicting warfarin sensitivity

Publications (1)

Publication Number Publication Date
MX2007007568A true MX2007007568A (es) 2008-03-11

Family

ID=36602356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007568A MX2007007568A (es) 2004-12-21 2005-12-21 Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina.

Country Status (18)

Country Link
US (2) US20060166239A1 (es)
EP (2) EP1831402B1 (es)
JP (1) JP4516990B2 (es)
KR (1) KR101178463B1 (es)
CN (1) CN101142322B (es)
AT (1) ATE470725T1 (es)
AU (1) AU2005319028B2 (es)
BR (1) BRPI0519570A2 (es)
CA (1) CA2591840C (es)
DE (1) DE602005021821D1 (es)
DK (1) DK1831402T3 (es)
ES (1) ES2347167T3 (es)
MX (1) MX2007007568A (es)
NZ (1) NZ556461A (es)
PL (1) PL1831402T3 (es)
PT (1) PT1831402E (es)
TW (1) TWI334886B (es)
WO (1) WO2006069339A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
JP5348840B2 (ja) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
ES2339710T5 (es) * 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
CA2911569C (en) * 2005-11-29 2019-11-26 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
WO2007133506A2 (en) * 2006-05-09 2007-11-22 University Of Louisville Research Foundation , Inc. Personalized medicine management software
US8039212B2 (en) * 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
US8688416B2 (en) * 2008-10-20 2014-04-01 Michael Fearon Methods and systems for improved pharmaceutical intervention in coagulation control
KR101157135B1 (ko) * 2008-12-29 2012-06-18 인제대학교 산학협력단 항응고제의 약물반응과 관련된 유전자의 변이 유전형 결정방법
US20100227776A1 (en) * 2009-03-05 2010-09-09 The Ohio State University Rapid Genotyping of SNPs
KR101386918B1 (ko) * 2010-06-01 2014-04-18 아크레이 가부시키가이샤 Ｖｋｏｒｃ１ 유전자의 -1639번째의 염기의 다형 검출법, 및 그것을 위한 핵산 프로브 및 키트
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
TWI564392B (zh) * 2012-08-21 2017-01-01 財團法人工業技術研究院 偵測生物材料的系統及方法
CN103173443B (zh) * 2013-03-22 2016-08-24 卫生部北京医院 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用
JP7228514B2 (ja) 2016-12-09 2023-02-24 ザ・ブロード・インスティテュート・インコーポレイテッド Ｃｒｉｓｐｒエフェクターシステムベースの診断法
BR112019019087A2 (pt) 2017-03-15 2020-05-12 The Broad Institute, Inc. Diagnóstico baseado em sistema efetor de crispr para detecção de vírus
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
CA3062858A1 (en) * 2017-05-12 2018-11-15 The Regents Of The University Of Michigan Individual and cohort pharmacological phenotype prediction platform
CA3087362A1 (en) 2018-01-29 2019-08-01 The Broad Institute, Inc. Crispr effector system based diagnostics
US20220220546A1 (en) 2019-03-14 2022-07-14 The Broad Institute, Inc. Sherlock assays for tick-borne diseases
CN110592206A (zh) * 2019-09-11 2019-12-20 上海交通大学 一种利用rs9934438检测华法药效的试剂盒
KR102506347B1 (ko) 2021-05-11 2023-03-03 충북대학교 산학협력단 와파린 치료에 따른 출혈 부작용 위험 예측용 다형성 마커 및 이를 이용한 와파린 치료에 따른 출혈 부작용 위험 예측 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
ES2339710T5 (es) * 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
JP4997113B2 (ja) * 2004-10-18 2012-08-08 ユニヴァーシティ オブ ワシントン 薬物反応を予測するための方法および組成物
US20080005732A1 (en) * 2006-05-11 2008-01-03 Coon Robert F Method and System for Integrating Software Update Services with Software Applications

Also Published As

Publication number Publication date
CA2591840C (en) 2012-07-10
CN101142322A (zh) 2008-03-12
ATE470725T1 (de) 2010-06-15
ES2347167T3 (es) 2010-10-26
TW200637918A (en) 2006-11-01
US20060166239A1 (en) 2006-07-27
PT1831402E (pt) 2010-09-10
KR101178463B1 (ko) 2012-09-07
WO2006069339A3 (en) 2006-10-12
US20110236885A1 (en) 2011-09-29
AU2005319028B2 (en) 2010-09-16
PL1831402T3 (pl) 2010-12-31
JP4516990B2 (ja) 2010-08-04
WO2006069339A8 (en) 2010-06-03
DK1831402T3 (da) 2010-09-20
DE602005021821D1 (de) 2010-07-22
CA2591840A1 (en) 2006-06-29
NZ556461A (en) 2009-12-24
EP2246445A1 (en) 2010-11-03
BRPI0519570A2 (pt) 2009-01-27
CN101142322B (zh) 2011-09-21
KR20080005179A (ko) 2008-01-10
HK1117571A1 (en) 2009-01-16
JP2008523844A (ja) 2008-07-10
EP1831402A2 (en) 2007-09-12
WO2006069339A2 (en) 2006-06-29
EP1831402B1 (en) 2010-06-09
AU2005319028A1 (en) 2006-06-29
TWI334886B (en) 2010-12-21

Similar Documents

Publication Publication Date Title
MX2007007568A (es) Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina.
NL301145I2 (nl) Tirbanibulin
IL244249A0 (en) Markers for gene expression predicting response to chemotherapy
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
IL182929A0 (en) Predicting response to chemotherapy using gene expression markers
WO2005099775A3 (en) Labeled anwexin for predicting the response to a therapeutic regimen
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
WO2008048119A3 (en) Methods of analysis of polymorphisms and uses thereof
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
MX2009007458A (es) Biomarcador para la medicina y la biologia de la reproduccion.
DK1842920T4 (da) Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
TW200636075A (en) Detection of nucleic acid variation by cleavage-amplification method
EA201291228A1 (ru) Биомаркер для детекции высокогорной адаптации и высокогорного отека легких
WO2009149359A8 (en) Survival predictor for diffuse large b cell lymphoma
EA201171171A1 (ru) Генетические маркеры степени тяжести рассеянного склероза
ATE523601T1 (de) Verfahren und zusammensetzungen zur vorhersage der reaktion auf warfarin
PL1753512T3 (pl) Tetrahydropirydotiofeny
WO2007058968A3 (en) Gene expression profiles and methods of use
DK1725656T3 (da) Serumfri suspensionskultursystem til mesenchymale progenitorceller
WO2008048902A3 (en) Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease
WO2006044686A3 (en) Methods and compositions for predicting drug responses
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
SG133515A1 (en) Scintillation proximity assay
PL1673472T3 (pl) Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general